Welcome to the NEJM Forum on the original research article just published in NEJM titled “A randomized, controlled trial of 3.0mg Liraglutide in weight management.” I'd like to thank the panel of experts in advance for their time and participation in this forum. I will be posting one question every day along with my co-moderators. I'm looking forward to the next 10 days and hope that we will have an interesting and engaging discussion. To start of the discussion, I would like to ask if the panel of experts would share their thoughts about the different proposed mechanisms for which Liraglutide mediates weight loss. In lower doses for diabetes management, GLP-1 agonists class drugs have been shown to increase glucose-dependent insulin secretion, decrease glucagon secretion, delay gastric emptying and increase satiety. Would there be any additional mechanistic benefits using a higher dose of treatment with 3.0mg, or is it a dose effect with the higher dosage producing a larger effect?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this challenge
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.